Celebrex in treatment of joint diseases in patients with risk factors of gastropathy and cardiovascular palhalodydevelopment
https://doi.org/10.14412/1995-4484-2004-1381
Abstract
Literature digest is presented concerning to gastrointestinal and cardiovascular safety of selective COX- 2 inhibitors including results of Russian clinico-endoscopic study of celebrex efficacy and tolerability in osteoarthritis (OA). Celebrex was administered to the pts with risk factors of gastrointestinal and cardiovascular adverse events development. Results of longstanding treatment of pts with OA and rheumatoid arthritis (RA) which were prospectively followed up are presented. Celebrex was shown to have high efficacy (about 90% responders) and good tolerability independently on age, duration of treatment and daily dose. Esophagogastroduodenoscopy revealed ulcer development in 4% pts with OA with history of ulcer and in 2,4% pts with RA.
References
1. <div><p>Adams P.F., G.E Hendershot М.А. Marano. Current Estimates from the National Health Interview Survey 1996. National Center for Health Statistics. Vital Health Stat. 10 (2000) , 1999.</p><p>Vane J.R, Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature (New Biol.), 1971, 231, 232-235</p><p>Насонов Е.Л. Нестероидные противовоспалительные препараты (перспективы применения в медицине) М., "Анко", 2000, 143 стр</p><p>Singh G., Diadohlopoulus G. Epidemiology of NSAID’S- induced gastroduodenal complication J. Rheumatol., 1999. 26 suppl., 18-24</p><p>Armstrong C.P., Blower A.L. Non-steroidal anti-inflammatory drugs and life threatening complication of peptic ulceration. Gut, 1987, 28, 527-532</p><p>Singh G., Ramey D.R., Morfield D. et.al. Gastrointestinal tract complications on nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. Arch. Intern. Med. 1996, 156, 1530-1536</p><p>Goldstein J., Boers М., Van Ingen H. et. al. Endoscopic gastroduodenal ulcers and age: increased incidence with traditional NSAIDs but non with Celecoxib. Abstr. accepted to: United Europen Gastroenterology Week (UEGW); Geneva, Oct. 19-24, 2002.</p><p>Janssen М., Dijkmans B., van der Sluijs F.A. Upper gastrointestinal complaints and complication in chronic rheumatic patients in comparison with other chronic diseases. Br.J.Rheum., 1992., 31, 747-752.</p><p>Насонов Е.Л. Ингибиторы циклооксигеназы 2: современная концепция. Тер. архив, 1999, II, 54-57.</p><p>Bensen W.G., Zhao S.Z., Burke Т.А. et.al. Upper gastrointestinal tolerability of Celecoxib, a COX-2 specific inhibitor, compared to napoxen and placebo. J. Rheum., 2000, 27, 1876-1883</p><p>Feldman М., McMahon A.T. Do cyclooxigenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann. Intern. Med., 2000, 132,134-139</p><p>E.C. Цветкова, Л.И. Алексеева. P.M. Балабанова и др. Эффективность и переносимость целебрекса при осте- артрозе (данные Российского исследования), Тер.ар- хив., 2001,5, 61-63</p><p>А.Е. Каратеев. Гастродуоденальная переносимость це- лекокснба (целебрекса) у больных остеоартрозом: эндоскопическая оценка. Тер. архив, 2001, 5, 63-64.</p><p>Epstein М., Safar М. Cardiovascular and renal effects of COX-2 specific inhibitors: emerging pathophysiological and clinical perspectives. J. Hypert., 2002, 20 (suppl. 6), 1-2</p><p>Whelton A., Fort J.G., Puma J.A. et.al. Cyclooxigenase-2 specific inhibitors and cardiorenal function: a randomized, controlled trial. Am. J. Ther., 2001, 9, 85-95</p><p>Solomon D.H., Glynn R., Levin R., Adams K, Nonsteroidal anti-inflammatory drugs and acute Myocardial Infarction. Arch. Int. Med., 2002, 162, 10671074.</p></div><br />
Review
For citations:
Chichasova N.V., Imametdinova G.R., Nassonov E.L. Celebrex in treatment of joint diseases in patients with risk factors of gastropathy and cardiovascular palhalodydevelopment. Rheumatology Science and Practice. 2004;42(1):39-42. (In Russ.) https://doi.org/10.14412/1995-4484-2004-1381
Views:
1679
Email this article 